Skip to main content

Table 4 Toxicity profile * in nine eligible patients who received a total of 51 cycles

From: A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors

 

Grade 2

Grade 3

Grade 4

Grade 3/4

 

No. of events (%)

No. of patients (%)

No. of events (%)

No. of patients (%)

No. of events (%)

No. of patients (%)

No. of patients (%)

Hematologic

       

 Anemia

27 (53)

6 (67)

12 (24)

7 (78)

5 (10)

2 (22)

7 (78)

 Thrombocytopenia

5 (10)

4 (44)

7 (14)

3 (33)

4 (8)

3 (33)

6 (67)

 Leucopenia

-

-

2 (4)

1 (11)

49 (96)

8 (89)

9 (100)

 Neutropenia

-

-

-

-

51 (100)

9 (100)

9 (100)

 Neutropenic fever

-

-

6 (12)

5 (56)

-

-

5 (56)

 Eye infection

-

-

1 (2)

1 (11)

-

-

1 (11)

 Nail infection

1 (2)

1 (11)

-

-

-

-

-

 Anorectal infection

-

-

1 (2)

1 (11)

-

-

1 (11)

Non-hematologic

       

 Headache

1 (2)

1 (11)

    

-

 Dysgeusia

1 (2)

1 (11)

-

-

-

-

-

 Oral mucositis

5 (10)

4 (44)

2 (4)

1 (11)

-

-

1 (11)

 Nausea

4 (8)

2 (22)

-

-

-

-

-

 Vomiting

9 (18)

6 (67)

-

-

-

-

-

 Abdominal pain

6 (12)

3 (33)

-

-

-

-

-

 Diarrhea

17 (33)

5 (56)

2 (4)

2 (22)

-

-

2 (22)

 Chest discomfort

1 (2)

1 (11)

-

-

-

-

-

 Pleural effusion

3 (6)

2 (22)

-

-

-

-

-

 Pericardial effusion

1 (2)

1 (11)

-

-

-

-

-

 Edema

1 (2)

1 (11)

-

-

-

-

-

 Peripheral neuropathy

6 (12)

2 (22)

9 (18)

1 (11)

-

-

1 (11)

 Tremor

1 (2)

1 (11)

-

-

-

-

-

 Muscle weakness

1 (2)

1 (11)

14 (27)

1 (11)

-

-

1 (11)

  1. *If a patient suffered from toxicity of more than one grade, each grade was counted separately.
  2. Abbreviations: -, none.